Please ensure Javascript is enabled for purposes of website accessibility

Teladoc Is Suing Amwell for Patent Infringement

By Eric Volkman – Updated Oct 14, 2020 at 5:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It accuses its rival of nine violations related to two products.

Two prominent companies in the burgeoning telehealth segment are at odds and will likely face each other in court. Teladoc (TDOC 0.69%) is suing American Well (AMWL 1.59%) for patent infringement over a digital scope and stethoscope the latter sells.

Earlier this week it came to light that Teladoc formally accused American Well (also known as Amwell) in a letter sent by its lawyers to Amwell management in mid-September. Teladoc believes that patents it obtained when it acquired healthcare tech specialist InTouch Technologies were infringed upon by two Amwell products, the Horus HD Digital Scope System and the Thinklabs One Digital Stethoscope.

Stethoscope and gavel on desk with caduceus ornament and books.

Image source: Getty Images.

All told, Teladoc is accusing Amwell of violating nine of its patents. In the letter, Teladoc demanded that Amwell immediately cease and desist selling and using the offending products, and respond to its accusations by Sept. 18.

It is not known if or when Amwell sent a formal response. It has not issued an official statement on the matter, although it referred to the letter in the registration statement it filed with the Securities and Exchange Commission prior to its IPO last month. The company wrote that "we believe that these claims lack merit and, if Teladoc attempts to bring these claims to court, we intend to defend against them vigorously."

Amwell pointed out that sales from the products in dispute comprised less than 5% of its 2019 revenue.

That might not be a comforting thought for investors; on Wednesday, they traded Amwell's stock down by 2.9%, a steeper fall than the S&P 500 index suffered on the day.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool has a disclosure policy.

Stocks Mentioned

Teladoc Health Stock Quote
Teladoc Health
$29.20 (0.69%) $0.20
Amwell Stock Quote
$3.83 (1.59%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.